What is the price target for Eli Lilly stock?

Analysts predict the market cap could reach $1 trillion, implying a stock price above the current $1,149.15.

An experimental obesity drug by Eli Lilly that showed high weight-loss efficacy in Phase 3 trials.

How has Eli Lilly stock performed over the past year?

The stock gained 50.31% over the past year, hitting a new 52-week high.

Eli Lilly Stock Prediction: On Track to $1 Trillion?

Eli Lilly (LLY) stock hits a fresh 52-week high at $1,149.15, driven by promising Phase 3 results for its obesity drug retatrutide. Analysts forecast the company's market cap could hit $1 trillion in a year.

June 9, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

stock price

1,149.15

one year gain

50.31%

Eli Lilly (NYSE:LLY) stock surged to a new 52-week high of $1,149.15, following positive Phase 3 trial data for its obesity drug retatrutide. Analysts believe the drug could become a first-line treatment for obesity, fueling expectations that the company's market capitalization will reach $1 trillion within a year.

Possible Drivers

Phase 3 retatrutide data: Showed high efficacy in weight loss, with analysts calling it a potential "first-line" obesity treatment.
Stock up 50.31% over the past year: Reflects growing investor confidence in Eli Lilly's competitive position in the obesity market.

Context

After a tough stretch in late 2025 and a shaky start to this year, the stock has regained strong momentum. This rally comes amid rising demand for obesity treatments, with the market projected to reach $100 billion by 2030.

Similar Moves in the Sector

Competitors like Novo Nordisk (NVO) have also seen strong gains thanks to Wegovy. However, retatrutide's early data may give Eli Lilly a competitive edge.

Frequently Asked Questions

The stock rose after positive Phase 3 results for its obesity drug retatrutide, boosting analyst expectations.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.